BCYC - VBL Therapeutics's Cancer Trial And Other News: The Good Bad And Ugly Of Biopharma
VBL Therapeutics reports progress for metastatic colorectal cancer trial
VBL Therapeutics (VBLT) announced the enrollment of the first two patients for its Phase 2 clinical trial of VB-111. The trial is designed to evaluate the potential of VB-111 used in combination with nivolumab for treating metastatic colorectal cancer. The company is collaborating with the National Cancer Institute under a Cooperative Research and Development Agreement for conducting this study.
The Phase 2 study is designed to investigate whether priming with VB-111 and further use of nivolumab may result in inducing anti-tumor immune response in